- Home
- CHI vs AQST Comparison
CHI vs AQST Comparison
Compare CHI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | AQST |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.3M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CHI | AQST |
|---|---|---|
| Price | $11.69 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 186.2K | ★ 6.6M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.70 | $2.12 |
| 52 Week High | $11.61 | $7.55 |
Technical Indicators
Market Signals| Indicator | CHI | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 42.48 |
| Support Level | $11.00 | $3.65 |
| Resistance Level | $11.60 | $4.18 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 65.00 | 53.10 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.